Observational Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jun 27, 2025; 17(6): 104693
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.104693
Relationship between glucagon and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus
Yi Sun, Ping Huang, Xiao-Qin Zhao, Zhu-Qi Tang, Tong-Tong Xu, Xin-Wei Wang, Zong-Xian Qi, Wei-Rong Lin, Min-You Li, Yun-Juan Gu
Yi Sun, Ping Huang, Xiao-Qin Zhao, Zhu-Qi Tang, Tong-Tong Xu, Xin-Wei Wang, Yun-Juan Gu, Department of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226000, Jiangsu Province, China
Zong-Xian Qi, Wei-Rong Lin, Min-You Li, R&D Department, Guangzhou Jinde Biotech Company Limited, Guangzhou 510000, Guangdong Province, China
Co-first authors: Yi Sun and Ping Huang.
Author contributions: Sun Y and Huang P contribute equally to this study as co-first authors; Sun Y wrote the first draft (including substantive translation); Huang P analyzed or synthesized the study data; Zhao XQ and Tang ZQ validated the results; Xu TT and Wang XW performed the experiments and data collection; Qi ZX and Lin WR provided the study materials, instrumentation, and analytical tools; Li MY managed and coordinated the planning and implementation of the research activities; Gu YJ designed the study.
Supported by Nantong Municipal Science and Technology Project, No. MS22019005, No. MSZ2023155 and No. JCZ2023004; Nantong University Hospital Research Hospital Construction Project, No. YJXYY202204-XKB09; and Guangzhou Jinde Biotechnology Company Self-selected Clinical Research Projects, No. HXKT20221024.
Institutional review board statement: The study was reviewed and approved by the ethics committee of Nantong University Affiliated Hospital (Approval No. 2018-k016).
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors disclosed no potential conflict of interest relevant to this article.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Data sharing statement: Dataset available from the corresponding author at desette@ntu.edu.cn. Participants gave informed consent for data sharing and the presented data are anonymized and risk of identification is low.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yun-Juan Gu, Department of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, No. 20 Xisi Road, Nantong 226000, Jiangsu Province, China. desette@ntu.edu.cn
Received: December 31, 2024
Revised: March 18, 2025
Accepted: May 26, 2025
Published online: June 27, 2025
Processing time: 177 Days and 19.7 Hours
Core Tip

Core Tip: Our study aims to explore the relationship between glucagon (GCG) and the development of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes mellitus (T2DM) patients, and the possible influencing factors. A total of 212 patients with T2DM were enrolled. We categorized the study subjects into two groups with and without MASLD by the ultrasound attenuation parameter (244 dB/m as cut-off value). We find fasting GCG, fasting C-peptide and liver stiffness measurement are risk factors for MASLD in patients with T2DM.